Latest Insider Transactions at Blueprint Medicines Corp (BPMC)
This section provides a real-time view of insider transactions for Blueprint Medicines Corp (BPMC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Blueprint Medicines Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Blueprint Medicines Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 18
2025
|
John Tsai Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,902
+23.58%
|
$499,456
$128.12 P/Share
|
|
Jun 18
2025
|
Lonnel Coats Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,902
+38.84%
|
$49,992,424
$12812.0 P/Share
|
|
Jun 18
2025
|
Habib J Dable Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,902
+23.58%
|
$499,456
$128.12 P/Share
|
|
Jun 18
2025
|
Alexis Borisy Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,902
+4.76%
|
$499,456
$128.12 P/Share
|
|
Jun 18
2025
|
Daniella Beckman Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,902
+20.93%
|
$499,456
$128.12 P/Share
|
|
Jun 03
2025
|
Percy H. Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,659
-2.35%
|
$337,693
$127.88 P/Share
|
|
May 27
2025
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
5,000
-1.66%
|
$505,000
$101.47 P/Share
|
|
May 27
2025
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.19%
|
$180,000
$36.05 P/Share
|
|
May 19
2025
|
Christina Rossi Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,274
-1.14%
|
$227,400
$100.84 P/Share
|
|
May 05
2025
|
Ariel Hurley Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,752
-4.84%
|
$283,456
$103.62 P/Share
|
|
May 05
2025
|
Ariel Hurley Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,752
+12.26%
|
$148,608
$54.13 P/Share
|
|
May 05
2025
|
Christina Rossi Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,274
-0.83%
|
$231,948
$102.28 P/Share
|
|
Apr 01
2025
|
Kate Haviland Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,498
-0.37%
|
$214,828
$86.88 P/Share
|
|
Mar 24
2025
|
Christina Rossi Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,274
-3.18%
|
$216,030
$95.02 P/Share
|
|
Mar 12
2025
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
7,500
-2.37%
|
$652,500
$88.0 P/Share
|
|
Mar 12
2025
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+4.48%
|
$270,000
$36.05 P/Share
|
|
Mar 06
2025
|
L. Becker Hewes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,232
-7.63%
|
$455,184
$87.7 P/Share
|
|
Mar 05
2025
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
5,766
-3.78%
|
$507,408
$88.8 P/Share
|
|
Mar 05
2025
|
L. Becker Hewes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,863
-12.0%
|
$427,944
$88.8 P/Share
|
|
Mar 05
2025
|
Ariel Hurley Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,326
-7.26%
|
$116,688
$88.8 P/Share
|
|
Mar 05
2025
|
Michael Landsittel Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,284
-6.76%
|
$464,992
$88.8 P/Share
|
|
Mar 05
2025
|
Philina Lee Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,733
-8.16%
|
$328,504
$88.8 P/Share
|
|
Mar 05
2025
|
Tracey L Mc Cain EVP & Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,262
-7.32%
|
$463,056
$88.8 P/Share
|
|
Mar 05
2025
|
Fouad Namouni PRESIDENT, R & D |
SELL
Open market or private sale
|
Direct |
6,489
-7.89%
|
$571,032
$88.8 P/Share
|
|
Mar 05
2025
|
Christina Rossi Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
6,495
-8.32%
|
$571,560
$88.8 P/Share
|
|
Mar 05
2025
|
Percy H. Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,530
-5.84%
|
$310,640
$88.8 P/Share
|
|
Mar 05
2025
|
Debra Durso Bumpus Chief People Officer |
SELL
Open market or private sale
|
Direct |
5,157
-9.42%
|
$453,816
$88.8 P/Share
|
|
Mar 05
2025
|
Kate Haviland Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,151
-8.75%
|
$1,421,288
$88.8 P/Share
|
|
Mar 03
2025
|
Ariel Hurley Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,203
-3.17%
|
$294,676
$92.23 P/Share
|
|
Mar 01
2025
|
Tracey L Mc Cain EVP & Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+13.28%
|
-
|
|
Mar 01
2025
|
Ariel Hurley Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,506
+23.25%
|
-
|
|
Mar 01
2025
|
Philina Lee Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+19.39%
|
-
|
|
Mar 01
2025
|
L. Becker Hewes Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+21.35%
|
-
|
|
Mar 01
2025
|
Debra Durso Bumpus Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+16.73%
|
-
|
|
Mar 01
2025
|
Fouad Namouni PRESIDENT, R & D |
BUY
Grant, award, or other acquisition
|
Direct |
13,200
+13.83%
|
-
|
|
Mar 01
2025
|
Michael Landsittel Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+12.33%
|
-
|
|
Mar 01
2025
|
Percy H. Carter Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+15.41%
|
-
|
|
Mar 01
2025
|
Christina Rossi Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,200
+14.47%
|
-
|
|
Mar 01
2025
|
Kate Haviland Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,200
+16.02%
|
-
|
|
Feb 20
2025
|
Christina Rossi Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,274
-3.39%
|
$216,030
$95.14 P/Share
|
|
Jan 21
2025
|
Kate Haviland Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,446
-0.96%
|
$159,060
$110.24 P/Share
|
|
Jan 21
2025
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
15,161
-3.09%
|
$1,652,549
$109.88 P/Share
|
|
Jan 21
2025
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.63%
|
$360,000
$36.05 P/Share
|
|
Jan 21
2025
|
Christina Rossi Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,274
-0.83%
|
$250,140
$110.39 P/Share
|
|
Jan 13
2025
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
5,000
-3.08%
|
$510,000
$102.28 P/Share
|
|
Jan 13
2025
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.98%
|
$180,000
$36.05 P/Share
|
|
Jan 13
2025
|
Ariel Hurley Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,250
-13.07%
|
$225,000
$100.0 P/Share
|
|
Jan 13
2025
|
Ariel Hurley Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+11.56%
|
$81,000
$36.05 P/Share
|
|
Dec 19
2024
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
15,000
-2.25%
|
$1,350,000
$90.1 P/Share
|
|
Dec 19
2024
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+8.0%
|
$540,000
$36.05 P/Share
|